STUDresearch · Peptide
PN-477
Also known as
PN477 · PN 477 · PN-477o · PN-477sc · Protagonist PN-477 · PTGX triple-G
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Niche talk
Systemic
Oral / SubQ
Metabolic / GLP-1 class
Systemic multi-agonist peptide.
What people say
PN-477 is Protagonist Therapeutics’ investigational triple GLP-1/GIP/glucagon receptor agonist peptide program, with a weekly subcutaneous candidate in Phase 1 and a once-daily oral candidate planned behind it.
Doses people talk about
Public material identifies once-daily oral and once-weekly subcutaneous designs. It does not authorize borrowing another incretin’s dose ladder.
How it may feel
No exposed-user diary or public human result was located. Current discussion is investor, professional and GLP-1 community anticipation; it cannot supply a PN-477-specific appetite, gastrointestinal or weight-loss experience curve.
Public human amountNot published
PN-477sc has entered Phase 1, but the reviewed SEC and company material did not disclose a human milligram amount.
Half-life & effect duration
- Half-life in the body
- Half-lifeNo settled estimate
- Felt duration people report
- Felt durationNo PN-477-specific firsthand timeline reported
Cycles people discuss
The development concept is chronic obesity treatment, not a forum cycle. No PN-477 titration or maintenance tradition can be inferred from retatrutide or another incretin.
Timing
The program is designed around once-weekly SubQ and once-daily oral administration. The reviewed public material does not establish meal, morning/evening or training placement.
Stacks
PN-477 is a standalone pipeline candidate, not an established stack ingredient. Comparisons with retatrutide or oral incretins are not evidence for combining them.
Watch for
No human AE table yet. Incretin-class GI/HR lore is borrowed, not measured.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
A public human PN-477 half-life was not located.
The SEC filing says the subcutaneous study has started and describes weekly versus daily intended administration; it does not report human pharmacokinetic results.
An initiated Phase 1 program and intended dosing frequency do not establish a measured elimination half-life.
- Protagonist Therapeutics, Inc. Form 10-Q for quarter ended June 30, 2026 (opens in a new tab)Obesity Program lines 871–888, especially PN-477 routes, intended intervals and Phase 1 status at lines 872–873.Sponsor-authored regulatory filing reports program status and design intent but no PN-477 human dose, PK result, adverse-event table or efficacy result.
Felt duration people report
No PN-477-specific felt-duration clock can be derived from the reviewed discussion.
A professional social post and a GLP-1 community article discuss expected convenience, efficacy and tolerability, but neither reports personal PN-477 exposure.
Pipeline commentary, hypothetical comparisons and reports about retatrutide cannot substitute for PN-477 human experience.
- Is Protagonist Therapeutics’ Triple-G Pill the Next Game-Changer in Obesity Treatment? (opens in a new tab)Post and visible comment lines 20–26.Professional anticipation from before Phase 1 initiation; no personal exposure, dose, clinical result or PN-477-specific tolerability evidence.
- Move Over Retatrutide, Protagonist Just Became Your Antagonist (opens in a new tab)PN-477 description and comparison lines 61–107; visible reader comment lines 165–168.Enthusiastic secondary community article written before PN-477sc Phase 1 initiation; discusses hypothetical future performance and retatrutide use, not PN-477 exposure.
What people say
- Oral optionality: The thing that makes it a tweet — daily pill *or* weekly pin. forum
- No n=1 album yet. If a gray vial shows up, identity is the first argument. forum
- Not a food-noise diary compound today. That job is still reta/tirz/sema. forum
- Reta-class hope: Weight-loss plus GI-tolerability plus fat-to-lean talk in the pressers people paste. Animal/preclinical, not a Phase 3 album. trial
- Mouse / dog / monkey charts: Vendor-adjacent write-ups claim big diet-induced-obesity loss and “vs reta” animal comparisons. Not human. animal
Doses people talk about
- Do not copy reta 2→4→8→12 mg onto PN-477. Different peptide. forum
- Do not copy orforglipron oral milligrams onto this. forum
- Gray-vial math is identity risk, not a protocol. forum
- Oral candidate: Once-daily swallow in company language — milligrams not public. trial
- SC candidate: Once-weekly pin in company language — milligrams not public. trial
- Framing: No human labeled milligrams. Not a reta ladder with this name on it. forum
How it may feel
- Now: The PN-477sc Phase 1 study has started, but no first-person exposure diaries or public human results were located. trialforum
- If someone buys a research vial anyway: There is no copied human time-course. Do not borrow reta week-by-week GI lore and stamp this name on it. forum
- Stop: No withdrawal story because almost nobody has a bottle with a history. forum
- Clinic clock: PN-477sc entered Phase 1 in 2026; the company anticipated PN-477o Phase 1 initiation in the first half of 2027. These are program milestones, not felt-effect timing. trial
Cycles people discuss
- Forum “cycle”: Doesn’t exist yet as a copied chart. forum
- If it ever has n=1s: Expect the usual incretin pattern — long titration, hold a tolerable step, regain talk after stop. That is class lore, not this molecule’s diary. forum
- Clinic model (planned): Chronic obesity therapy, not an 8-week blast. trial
Timing
- Reta’s ~6-day T½ is not this peptide’s T½. forum
- GI / HR class cautions from other incretins get borrowed in comments. Borrowed, not measured here. forum
- No public human half-life as of this card. trial
- Weekly SC vs daily oral is the design split, not a measured T½ everyone quotes. trial
More on what it is
- Amylin rumor: One X post said it also hits amylin. Company nomination language is triple-G only. Treat extra-receptor talk as rumor. forum
- Not orforglipron. Different oral GLP story (small molecule vs this peptide). forum
- What it is: Protagonist Therapeutics’ obesity candidate. Same three receptors as retatrutide (GLP-1, GIP, glucagon). They named an oral once-daily (PN-477o) and a weekly pin (PN-477sc). trial
- Why people talk about it: 2026 X is “why is no one talking about PN-477?” Nasdaq company, reta-competitor framing. Diaries are still thin. forum
- How it works (plain): Triple-G — appetite plus the glucagon “energy expenditure / liver fat” arm people already argue about on reta. trial
- Oral vs pin: The pitch is a swallow that is supposed to compete with injectables, plus a weekly SC backup. Human PK is not a public label yet. trial
Stacks
- Solo pipeline name — not a stack ingredient in 2026 screenshots. forum
- Compared with reta, not stacked with reta in sensible talk. Two triple-Gs is not a copied protocol. forum
- Orforglipron / amycretin / maridebart sit in the same “next oral / next multi-agonist” drawer. forum
Storage notes
- Clinic product isn’t a BAC-water vial yet. forum
- If a “PN-477” lyophilized listing appears, treat identity as unproven. forum
Watch for
- No human AE table yet. Incretin-class GI/HR lore is borrowed, not measured. forum
- Amylin-receptor rumor is not company language. forum
- Gray-vial identity. forum
- Not reta. Don’t run a reta ladder and call it this. forum
- Pipeline dates slip. “Phase 1 in 2026” is a presser, not a bottle. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.